Rapid Response

Do We Need Better Lipid Tools for Cardiovascular Risk Assessment?

Authors: Manfredi Rizzo, MD, PhD, Kaspar Berneis, MD

Abstract

Cardiovascular diseases still represent the major cause of death in most developed countries and ultimately kill as many men as women.1 In the last decades, the management of a number of “traditional” risk factors (including obesity, diabetes, smoking, hypertension, and hypercholesterolemia) has led to a significant reduction in cardiovascular morbidity and mortality, but new tools for risk assessment are needed to develop more effective strategies for primary and secondary prevention.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii)—final report. Circulation 2002;106:3143–3421.
 
2. Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc 1999;58:163–169.
 
3. Ingelsson E, Schaefer E, Contois J, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776–785.
 
4. Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 2006;44:1015–1021.
 
5. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Athereroscler Thromb 2005;12:237–239.